Trinity Biotech plc (TRIB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Trinity Biotech plc (TRIB) has a cash flow conversion efficiency ratio of 0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.55 Million) by net assets ($-71.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TRIB stock market capitalisation for the company's overall valuation and market capitalisation.
Trinity Biotech plc - Cash Flow Conversion Efficiency Trend (1993–2025)
This chart illustrates how Trinity Biotech plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Trinity Biotech plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trinity Biotech plc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Trinity Biotech plc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENEFI Energiahatekonysagi Nyrt
BUD:ENEFI
|
-0.013x |
|
AS Latvijas Juras medicinas centrs
MU:UOM
|
-0.098x |
|
Weststar Industrial Ltd
AU:WSI
|
-0.175x |
|
Rebosis
JSE:REB
|
-0.010x |
|
Intertainment AG
XETRA:ITN
|
0.016x |
|
Pollen Street PLC
LSE:POLN
|
0.069x |
|
Hyterra Ltd
AU:HYT
|
-0.032x |
|
Eko Export SA
WAR:EEX
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Trinity Biotech plc (1993–2025)
The table below shows the annual cash flow conversion efficiency of Trinity Biotech plc from 1993 to 2025. View Trinity Biotech plc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-71.98 Million | $-5.93 Million | 0.082x | -30.86% |
| 2024-12-31 | $-35.18 Million | $-4.19 Million | 0.119x | -75.31% |
| 2023-12-31 | $-23.95 Million | $-11.56 Million | 0.483x | +14.01% |
| 2022-12-31 | $-2.18 Million | $-921.00K | 0.423x | +101.02% |
| 2021-12-31 | $-319.00K | $13.24 Million | -41.498x | -287.64% |
| 2020-12-31 | $-2.22 Million | $23.75 Million | -10.705x | -1021.70% |
| 2019-12-31 | $4.71 Million | $5.47 Million | 1.161x | +637.81% |
| 2018-12-31 | $44.05 Million | $6.93 Million | 0.157x | -15.26% |
| 2017-12-31 | $65.20 Million | $12.11 Million | 0.186x | +46.68% |
| 2016-12-31 | $108.73 Million | $13.77 Million | 0.127x | +119.62% |
| 2015-12-31 | $213.89 Million | $12.34 Million | 0.058x | -27.88% |
| 2014-12-31 | $196.97 Million | $15.75 Million | 0.080x | +25.02% |
| 2013-12-31 | $183.01 Million | $11.71 Million | 0.064x | -45.98% |
| 2012-12-31 | $169.38 Million | $20.06 Million | 0.118x | -12.52% |
| 2011-12-31 | $151.33 Million | $20.48 Million | 0.135x | -17.11% |
| 2010-12-31 | $141.29 Million | $23.07 Million | 0.163x | -12.05% |
| 2009-12-31 | $79.34 Million | $14.73 Million | 0.186x | +14.05% |
| 2008-12-31 | $65.91 Million | $10.73 Million | 0.163x | +45.14% |
| 2007-12-31 | $136.84 Million | $15.35 Million | 0.112x | +154.62% |
| 2006-12-31 | $167.26 Million | $7.37 Million | 0.044x | -36.08% |
| 2005-12-31 | $133.62 Million | $9.21 Million | 0.069x | +18957.79% |
| 2004-12-31 | $116.14 Million | $42.00K | 0.000x | -99.19% |
| 2003-12-31 | $80.26 Million | $3.60 Million | 0.045x | -75.75% |
| 2002-12-31 | $62.91 Million | $11.65 Million | 0.185x | +106.90% |
| 2001-12-31 | $56.53 Million | $5.06 Million | 0.090x | +63.09% |
| 2000-12-31 | $55.04 Million | $3.02 Million | 0.055x | -67.36% |
| 1999-12-31 | $22.72 Million | $3.82 Million | 0.168x | +345.55% |
| 1998-12-31 | $14.60 Million | $-1.00 Million | -0.068x | +65.26% |
| 1997-12-31 | $7.10 Million | $-1.40 Million | -0.197x | +41.94% |
| 1996-12-31 | $10.60 Million | $-3.60 Million | -0.340x | -218.40% |
| 1995-12-31 | $7.50 Million | $-800.00K | -0.107x | +95.53% |
| 1994-12-31 | $1.30 Million | $-3.10 Million | -2.385x | -208.01% |
| 1993-12-31 | $3.10 Million | $-2.40 Million | -0.774x | -- |
About Trinity Biotech plc
Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually tr… Read more